Name
Disparities in monoclonal antibody (mAb) treatment usage in the Military Health System during the COVID-19 pandemic
Speakers
Content Presented on Behalf of
Uniformed Services University
Services/Agencies represented
Uniformed Services University (USU), Other/Not Listed
Session Type
Posters
Room#/Location
Prince Georges Exhibit Hall
Focus Areas/Topics
Clinical Care
Learning Outcomes
Following this session, the attendee will be able to:
1. Be aware of usage rates for Bamlanivimab, REGEN-CoV, and Bamlanivimab-Etesevimab in the MHS between 2020-2022.
2. Identify potential disparities based on race, age, and socioeconomic status in mAb usage within the MHS during the COVID-19 pandemic and discuss the implications of these inequities.
3. Suggest potential measures to reduce differences in mAb usage such as outreach, policy changes, and increased accessibility.
1. Be aware of usage rates for Bamlanivimab, REGEN-CoV, and Bamlanivimab-Etesevimab in the MHS between 2020-2022.
2. Identify potential disparities based on race, age, and socioeconomic status in mAb usage within the MHS during the COVID-19 pandemic and discuss the implications of these inequities.
3. Suggest potential measures to reduce differences in mAb usage such as outreach, policy changes, and increased accessibility.
Session Currently Live